239 related articles for article (PubMed ID: 21819803)
1. [Evidence-based therapeutic drug monitoring for efavirenz].
Solas C; Gagnieu MC;
Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Solas C; Gagnieu MC;
Therapie; 2011; 66(3):197-205. PubMed ID: 27393199
[TBL] [Abstract][Full Text] [Related]
3. [Evidence-based therapeutic drug monitoring for nevirapine].
Muret P; Piedoux S; Solas C; Quaranta S;
Therapie; 2011; 66(3):187-95. PubMed ID: 21819802
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz: a review.
Vrouenraets SM; Wit FW; van Tongeren J; Lange JM
Expert Opin Pharmacother; 2007 Apr; 8(6):851-71. PubMed ID: 17425480
[TBL] [Abstract][Full Text] [Related]
8. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
[TBL] [Abstract][Full Text] [Related]
9. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
10. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
[TBL] [Abstract][Full Text] [Related]
11. [Evidence-based therapeutic drug monitoring of atazanavir].
Solas C; Muret P;
Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
[TBL] [Abstract][Full Text] [Related]
13. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
[TBL] [Abstract][Full Text] [Related]
15. [Evidence-based therapeutic drug monitoring for saquinavir].
Muret P; Solas C;
Therapie; 2011; 66(3):207-12. PubMed ID: 21819804
[TBL] [Abstract][Full Text] [Related]
16. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
[TBL] [Abstract][Full Text] [Related]
17. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
